Anna Kazanchyan, MD

Chairwoman and CEO at Saghmos Therapeutics

Speaker

Dr. Kazanchyan is a biotechnology executive with 20 years of experience at marquee Wall Street firms, biopharmaceutical companies and as an entrepreneur. She has a unique combination of equity research, business/clinical/regulatory strategy as well as business development and investor relations experience and expertise.

Dr. Kazanchyan is also a member of the Board of Directors and the Compensation Committee for Foamix Pharmaceuticals (NASDAQ: FOMX). She serves as a coach for the WomenInBio's BoardRoom Ready initiative. In addition, she is an expert witness on matters of lost business opportunities, valuation, causation and damages calculation. Dr. Kazanchyan is the Founder, CEO and Chairwoman for Saghmos Therapeutics, a company focused on the prevention of contrast-induced acute kidney injury. She is also a founder and Managing Partner of Primary i-Research, LLC, where she provides due diligence to leading healthcare investment funds and has to date evaluated investment prospects of >200 biopharma products as well as companies based on the scientific, clinical, regulatory, and commercial outlook for their products. In addition, Dr. Kazanchyan is an Executive Advisor to CEOs of biopharmaceutical companies (start-ups to global companies) and has advised companies on matters related to business development, business/competitive intelligence, regulatory strategy, marketing, investor relations and commercial/competitive landscape. Previously, she was SVP, Business Development and Product Development at Ovid Therapeutics, a company focused on rare neurological disorders. Dr. Kazanchyan was also Senior Biotechnology Analyst at Wachovia Securities, and was a member of the #1 and #2 Institutional-Investor ranked Biotechnology Equity Research teams at Goldman Sachs and Citigroup, respectively. Dr. Kazanchyan received an M.D. from Harvard Medical School and a B.A. in Biology, summa cum laude, from Clark University